Amicus Therapeutics (FOLD) Misses Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amicus Therapeutics Announces First Quarter 2015 Financial Results and Corporate Updates
May 5, 2015 4:00 PM EDTMarketing Submissions for Migalastat Monotherapy for Fabry Disease on Track for 2Q15 in Europe and 2H15 in United States Net Cash Spend Guidance Updated to $100-$110 Million on Accelerated Commercialization and Manufacturing Next-Generation Pompe ERT Set to Enter Clinic in 2H15
CRANBURY, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced financial results for the first quarter ended March... More
